空气污染和egfr突变流行的世界地图。

IF 2.5 3区 医学 Q2 ONCOLOGY
Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona
{"title":"空气污染和egfr突变流行的世界地图。","authors":"Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona","doi":"10.1007/s12094-025-04039-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>The objective of this study was to analyze the association between mean PM<sub>2.5</sub> levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.</p><p><strong>Patients and methods: </strong>We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R<sup>2</sup> values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM<sub>2.5</sub> data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM<sub>2.5</sub> levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.</p><p><strong>Results: </strong>The association between PM<sub>2.5</sub> levels and EGFR-mutant prevalence ranged between moderate and weak (R<sup>2</sup> = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R<sup>2</sup> < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM<sub>2.5</sub>, 46.9% and 45.7%, respectively), the association was inconsistent.</p><p><strong>Conclusions: </strong>The discrepancy between PM<sub>2.5</sub> levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM<sub>2.5</sub> levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM<sub>2.5</sub> with EGFR-mutated lung cancer development.</p>","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A world map of air pollution and EGFR-mutant prevalence.\",\"authors\":\"Leonardo Rojas, Guillermo Villacampa, Daniel Shao Weng Tan, Oscar Arrieta, Jairo Zuluaga, Andrés Felipe Cardona\",\"doi\":\"10.1007/s12094-025-04039-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>The objective of this study was to analyze the association between mean PM<sub>2.5</sub> levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.</p><p><strong>Patients and methods: </strong>We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R<sup>2</sup> values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM<sub>2.5</sub> data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM<sub>2.5</sub> levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.</p><p><strong>Results: </strong>The association between PM<sub>2.5</sub> levels and EGFR-mutant prevalence ranged between moderate and weak (R<sup>2</sup> = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R<sup>2</sup> < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM<sub>2.5</sub>, 46.9% and 45.7%, respectively), the association was inconsistent.</p><p><strong>Conclusions: </strong>The discrepancy between PM<sub>2.5</sub> levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM<sub>2.5</sub> levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM<sub>2.5</sub> with EGFR-mutated lung cancer development.</p>\",\"PeriodicalId\":50685,\"journal\":{\"name\":\"Clinical & Translational Oncology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical & Translational Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12094-025-04039-0\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-04039-0","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:本研究的目的是分析2000年至2020年PM2.5平均水平与全球表皮生长因子受体(EGFR)突变发生率之间的关系。患者和方法:我们拟合了非小细胞肺癌(NSCLC)总数加权的线性回归模型来估计关联强度。计算调整后的R2值,值越接近1表明相关性越强。来自69个国家的数据可供使用。2015-2020年PM2.5数据来自经济合作与发展组织数据库(https://stats.oecd.org/)。平均PM2.5水平、EGFR突变流行率数据和总NSCLC病例来自已发表的文献和国家癌症登记处。结果:PM2.5水平与egfr突变患病率之间的相关性介于中等和弱之间(R2 = 0.34, 95%可信区间[CI] 0.02-0.67)。相关性进一步减弱(R2分别为2.5、46.9%和45.7%),相关性不一致。结论:PM2.5水平与egfr突变肺癌患病率之间的差异可能归因于肺癌基因组谱获取的差异、对egfr突变患病率的潜在高估或低估、各国PM2.5水平的不均匀性、包括所有肺癌患者而不考虑吸烟模式,以及其他因素,如基因组背景和血统。这些因素应被视为将PM2.5与egfr突变肺癌发展直接联系起来的潜在限制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A world map of air pollution and EGFR-mutant prevalence.

Purpose: The objective of this study was to analyze the association between mean PM2.5 levels from 2000 to 2020 and the prevalence of epidermal growth factor receptor (EGFR) mutations worldwide.

Patients and methods: We fitted linear regression models weighted by the total number of non-small cell lung cancer (NSCLC) to estimate the association strength. Adjusted R2 values were calculated, with values closer to 1 indicating a stronger association. Data from sixty-nine countries were available. PM2.5 data for 2015‒2020 were obtained from the Organisation for Economic Co-operation and Development database ( https://stats.oecd.org/ ). Mean PM2.5 levels, EGFR mutation prevalence data, and total NSCLC cases were acquired from published literature and national cancer registries.

Results: The association between PM2.5 levels and EGFR-mutant prevalence ranged between moderate and weak (R2 = 0.34, 95% Confidence interval [CI] 0.02‒0.67). The association further weakened (R2 < 0.15 in all comparisons) when stratified by area (European, Asian, or Latin American). Although certain countries had high air pollution and EGFR-mutant lung cancer prevalence (China: PM2.5, 46.9% and 45.7%, respectively), the association was inconsistent.

Conclusions: The discrepancy between PM2.5 levels and the prevalence of EGFR-mutant lung cancer could be attributed to differences in access to lung cancer genomic profiling, potential over- or underestimation of EGFR-mutant prevalence, non-homogeneous PM2.5 levels within countries, inclusion of all patients with lung cancer regardless of smoking patterns, and other factors, such as genomic background and ancestry. These factors should be considered as potential limitations in directly associating PM2.5 with EGFR-mutated lung cancer development.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
2.90%
发文量
240
审稿时长
1 months
期刊介绍: Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信